Preview

Онкогематология

Расширенный поиск

ЛЕЧЕНИЕ РЕЦИДИВОВ И РЕЗИСТЕНТНЫХ ФОРМ ЛИМФОМЫ ХОДЖКИНА

https://doi.org/10.17650/1818-8346-2017-12-2-8-13

Полный текст:

Аннотация

Благодаря стремительным успехам в развитии онкогематологии за полвека лимфома Ходжкина (ЛХ) превратилась из фатального в наиболее курабельное лимфопролиферативное заболевание. Несмотря на достигнутые успехи, 5–10 % больных ЛХ первично рефрактерны и 10–30 % рецидивируют после инициальной терапии. Проведение терапии 2-й линии с последующей трансплантацией аутологичных гемопоэтических стволовых клеток является стандартом лечения и позволяет достичь длительных ремиссий у 50 % больных. Появление брентуксимаба ведотина, представляющего конъюгат итостатика и антитела к CD30, кардинально изменило возможности терапии рецидивов и резистентных форм ЛХ и значимо улучшило прогноз заболевания. В статье представлен обзор литературы, посвященной лечению рецидивов и резистентных форм лимфомы Ходжкина.

Об авторе

Е. А. Барях
ГБУЗ «Городская клиническая больница № 52» Департамента здравоохранения города Москвы; ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Россия
Контакты: Елена Александровна Барях - 123182 Москва, ул. Пехотная, 3


Список литературы

1. Josting A.; Franklin J.; May M. et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002;20(1):221–30. DOI: 10.1200/JCO.2002.20.1.221.

2. Bonfante V.; Santoro A.; Viviani S. et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997;15(2):528–34. DOI: 10.1200/JCO.1997.15.2.528.

3. Radman I.; Basić N.; Labar B. et al. Longterm results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Ann Oncol 2002;13(10):1650–5. PMID: 12377656.

4. Ramchandren R. Advances in the Treatment of Relapsed or Refractory Hodgkin's Lymphoma. Oncologist 2012;17(3):367–76. DOI: 10.1634/theoncologist.2011-0258.

5. Schmitz N.; Pfistner B.; Sextro M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002;359:2065–71. DOI: 10.1016/S0140-6736(02)08938-9.

6. Martin A.; Fernàndez-Jiménez M.C.; Caballero M.D. et al. Long-term follow-up in patients treated with mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001;113:161–71. PMID: 11328296.

7. Moskowitz C.H.; Nimer S.D.; Zelenetz A.D. et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model.Blood 2001;97:616–23. PMID: 11157476.

8. Engert A.; Diehl V.; Franklin J. et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548–54. DOI: 10.1200/JCO.2008.19.8820.

9. Bartlett N.L.; Niedzwiecki D.; Johnson J.L. et al. Gemcitabine; vinorelbine; and pegylated liposomal doxorubicin (GVD); a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071–9. DOI: 10.1093/annonc/mdm090.

10. Baetz T.; Belch A.; Couban S. et al. Gemcitabine; dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762–1767. PMID: 14630682

11. Stokoe C.T.; Ogden J.; Jain V.K. Activity of infusional etoposide; vincristine; and doxorubicin with bolus cyclophosphamide (EPOCH) in relapsed Hodgkin's disease. The Oncologist 2001;6:428–34. PMID: 11675520.

12. Aparicio J.; Segura A.; Garcerà S. et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999;10:593–5. PMID: 10416011.

13. Josting A.; Rudolph C.; Reiser M. et al. Time-intensified dexamethasone/cisplatin/ cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002;13:1628–35. PMID: 12377653

14. Ferme C.; Bastion Y.; Lepage E. et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995;6:543–9. PMID: 8573532.

15. Vigouroux S.; Milpied N.; Andrieu J.M. et al. Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy. Bone Marrow Transplant 2002;29:833–42. DOI: 10.1038/sj.bmt.1703547.

16. Ferme C.; Mounier N.; Divine M. et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002;20:467–75. DOI: 10.1200/JCO.2002.20.2.467.

17. Stiff P.J.; Unger J.M.; Forman S.J. et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003;9:529–39. PMID: 12931122.

18. Tarella C.; Cuttica A.; Vitolo U. et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003;97:2748–59. DOI: 10.1002/cncr.11414.

19. Popat U.; Hosing C.; Saliba R.M. et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:1015–23. DOI: 10.1038/sj.bmt.1704483.

20. Lavoie J.C.; Connors J.M.; Phillips G.L. et al. High-dose chemotherapy and autologousstem cell transplantation for primary refractory orrelapsed Hodgkin lymphoma: longterm outcome in the first 100 patientstreated in Vancouver.Blood 2005;106:1473–8. DOI: 10.1182/blood-2004-12-4689.

21. Morabito F.; Stelitano C.; Luminari S. et al. The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Bone Marrow Transplant; 2006;37:283–8. DOI: 10.1038/sj.bmt.1705235.

22. Czyz J.; Dziadziuszko R.; Knopinska-Postuszuy W. et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 2004;15:1222–30. DOI: 10.1093/annonc/mdh304.

23. Schellong G.; Dorffel W.; Claviez A. et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005;23:6181–9. DOI: 10.1200/JCO.2005.07.930.

24. Sieniawski M.; Franklin J.; Nogova L. et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007;25:2000–5. DOI: 10.1200/JCO.2006.10.1386.

25. Viviani S.; Di Nicola M.; Bonfante V. et al. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymph 2010;51:1251–9. DOI: 10.3109/10428194.2010.486090.

26. Garfin P.M.; Link M.P.; Donaldson S.S. et al. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution. Biol Blood Marrow Transplant 2015;21:326–34. DOI: 10.1016/j.bbmt.2014.10.020.

27. Nieto Y.; Popat U.; Anderlini P. et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013;19:410–7. DOI: 10.1016/j.bbmt.2012.10.029.

28. McCarthy P.L. Jr.; Hahn T.; Hassebroek A. et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America; 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013;19:1116–23. DOI: 10.1016/j.bbmt.2013.04.027

29. Puig N.; Pintilie M.; Seshadri T. et al. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. Haematologica 2010;95:1496–502. DOI: 10.3324/haematol.2009.019943.

30. Viviani S.; Zinzani P.L.; Rambaldi A. et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203–12. DOI: 10.1056/NEJMoa1100340

31. Vaklavas C.; Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 2012;3(4):209–25. DOI: 10.1177/2040620712443076.

32. Francisco J.A.; Cerveny C.G.; Meyer D.L.; Mixan BJ; Klussman K; Chace DF et al. cAC10-vcMMAE; an anti-CD30- monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102(4):1458–65. DOI: 10.1182/blood-2003-01-0039.

33. Sutherland M.S.; Sanderson R.J.; Gordon K.A. et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptidelinked anti-CD30-auristatin conjugates. J Biol Chem 2006;281:10540–7. DOI: 10.1074/jbc.M510026200.

34. Oflazoglu E.; Stone I.J.; Gordon K.A.; GrewalI.S.; van Rooijen N.; Law C.L.; Gerber H.P. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 2007;110(13):4370–2. DOI: 10.1182/blood-2007-06-097014

35. Müller P.; Martin K.; Theurich S. et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res 2014;2(8):741–55. DOI: 10.1158/2326-6066.CIR-13-0198.

36. Garda S.J.; Angela Epp A.; Law C.L. Brentuximab vedotin-mediated immunogenic cell death. AACR 106th Annual Meeting 2015;April 18–22; 2015;Philade; Abstract 2469.

37. Moskowitz C.H.; Nademanee A.; Masszi T. et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised; double-blind; placebo-controlled; phase 3 trial. Lancet 2015;385(9980):1853–62. DOI: 10.1016/S0140-6736(15)60165-9.

38. Moskowitz A.J.; Schöder H.; Yahalom J. et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide; carboplatin; and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a nonrandomised; open-label; single-centre; phase 2 study. Lancet Oncol 2015;16(3):284–92. DOI: 10.1016/S1470-2045(15)70013-6.

39. Moskowitz A.J.; Hamlin P.A.; Perales M-A. et al. Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol 2013;31(4):456–60. DOI: 10.1200/JCO.2012.45.3308.

40. LaCasce A.S.; Bociek G.; Sawas A. et al. Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen forPatientswith Relapsed or Refractory Hodgkin Lymphoma. Blood; 2015;126(23):3982.

41. Garcia-SanzR.; SuredaA.;Alonso-Alvarez S. et al. Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood 2015;126(23):582.

42. Bartlett N.L.; Chen R.; Fanale M.A. et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 2014;7:24. DOI: 10.1186/1756-8722-7-24


Для цитирования:


Барях Е.А. ЛЕЧЕНИЕ РЕЦИДИВОВ И РЕЗИСТЕНТНЫХ ФОРМ ЛИМФОМЫ ХОДЖКИНА. Онкогематология. 2017;12(2):8-13. https://doi.org/10.17650/1818-8346-2017-12-2-8-13

For citation:


Baryakh E.A. TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA. Oncohematology. 2017;12(2):8-13. (In Russ.) https://doi.org/10.17650/1818-8346-2017-12-2-8-13

Просмотров: 2416


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1818-8346 (Print)
ISSN 2413-4023 (Online)